Upgraded listing would provide increased transparency and enhanced trading efficiency.

ESCONDIDO, CA / ACCESSWIRE / November 16, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) (“CBSC” or the “Company”) is pleased to announce that it has submitted its application to uplist to the OTCQB® Venture Market.

The application itself is not a guarantee of acceptance by OTC MARKETS to go from the Company’s current OTC PINK status to uplisting onto the OTCQB®. However, CB Scientific previously engaged MaloneBailey LLP to conduct a Public Company Accounting Oversight Board (PCAOB) audit and has appointed sufficient independent directors, both key requirements to be considered for uplisting. 

“If accepted, uplisting to the OTCQB® would be a critically important step for the Company as we continue to execute our business plan,” said Charles Martin, Chief Executive Officer of CB Scientific. “Additionally, achieving such an auspicious milestone will certainly better position us to meet required listing standards as we work towards achieving one of our longer-term objectives of becoming a Nasdaq Capital Markets-listed company,” he added.

The Company believes that an uplist to the OTCQB® would provide enhanced investor benefits, including more comprehensive compliance requirements, higher reporting standards, and greater access to analyst coverage.

As additional new developments occur, CB Scientific plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

About CB Scientific, Inc.
CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse – dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE: CB Scientific, Inc.